Abstract:Background The signal transducer and activator of transcription 6 (Stat6), a member of the family of DNA-binding proteins, has been identified as a critical cell differentiation modulator in breast cancer cells. As of yet, the mechanisms underlying this function have remained largely unknown. To further elucidate the role of Stat6 in breast cancer development, we investigated the consequences of exogenous Stat6 expression. Methods Proliferation assays and flow cytometry assays were conducted to evaluate the putative role of Stat6 on cell proliferation. To this end, we produced synchronized cells after a double thymidine block, as confirmed by FACS analysis. mRNA levels of Stat6 were measured by RNase protection analysis. To confirm the interaction among proteins, we employed GST pull-down assays and immunoprecipitation assays. Luciferase assays and ChIP assays were used to assess the transcriptional activity. Results Compared to control breast cancer cells, we found that exogenous Stat6 expression plays a critical role in controlling cell proliferation. Also in different breast tumor cell lines, endogenous Stat6 expression was found to be positively related to a lower proliferation rate. Interestingly, in human breast cancer cells Stat6 functions in G1/S cell cycle progression, and the growth-inhibitory effect of Stat6 was shown to be mediated by induction of the G1 cyclin-dependent kinase inhibitors p21 Cip1/WAF1 (p21) and p27 Kip1 (p27). Simultaneously, G1-related cyclin/cyclin-dependent kinase activities and pRB phosphorylation were markedly reduced, and cell cycle progression was blocked in the G1 phase. Stat6 knockdown resulted in enhanced cell proliferation and a decrease in p21 and p27 mRNA levels in the steroid-responsive and non-responsive T-47D and MDA-MB-231 cell lines, respectively. In addition, the stimulatory effect of Stat6 on p21 and p27 gene transcription was found to be associated with interaction of Stat6 with the transcription factor Sp1 at the proximal Sp1-binding sites in their respective promoters. Conclusions Together, these results identify Stat6 as an important cell differentiation regulatory protein functioning, at least in part, by interacting with Sp1 to activate the p21 and p27 gene promoters in breast cancer cells.

The anti-proliferative effects of type I IFN involve STAT6-mediated regulation of SP1 and BCL6

The Importance of Stat6 Regulated Genes Activated by Type I Interferon

Bcl6 Sets a Threshold for Antiviral Signaling by Restraining IRF7 Transcriptional Program

Enhanced IFN Sensing by Aggressive Chronic Lymphocytic Leukemia Cells

Type I IFN induced IL1-Ra expression in hepatocytes is mediated by activating STAT6 through the formation of STAT2: STAT6 heterodimer.

Type I Interferon Activates PD-1 Expression Through Activation of the STAT1-IRF2 Pathway in Myeloid Cells

Data from Type I Interferon Regulates a Coordinated Gene Network to Enhance Cytotoxic T Cell–Mediated Tumor Killing

Type I Interferon Suppresses Tumor Growth Through Activating the STAT3-granzyme B Pathway in Tumor-Infiltrating Cytotoxic T Lymphocytes

Biologic consequences of Stat1-independent IFN signaling

Noncanonical NF-κB Pathway Controls the Production of Type I Interferons in Antiviral Innate Immunity

Hyper-activated IRF-1 and STAT1 contribute to enhanced interferon stimulated gene (ISG) expression by interferon alpha and gamma co-treatment in human hepatoma cells.

Type I Interferons Exert Anti-Tumor Effect Via Reversing Immunosuppression Mediated by Mesenchymal Stromal Cells.

Hyper-activated IRF-1 and STAT1 contribute to enhanced Interferon stimulated gene (ISG) expression by Interferon α and γ co-treatment in human hepatoma cells

Type I Interferons and Il-12: Convergence and Cross Regulation among Mediators of Cellular Immunity.

Sequential Activation of Protein Kinase C Δ and JNK is Required for Interferon-Α-induced Expression of IFIT4

Abstract 2350: Type I Interferon Suppresses Tumor Growth Through Activating the STAT3-granzyme B Pathway in Tumor-Infiltrating Cytotoxic T Lymphocytes

Stat6 Cooperates with Sp1 in Controlling Breast Cancer Cell Proliferation by Modulating the Expression of P21 Cip1/WAF1 and P27 Kip1

Interferon-α inhibits CD4 T cell responses to interleukin-7 and interleukin-2 and selectively interferes with Akt signaling

A Dual Role of Type I Interferons in Antitumor Immunity

Reconstructing the JAK/STATs Signal Pathway Restored the Anti-Proliferative Response of MHCC97 on Interferon Alpha

Sequential Activation Of Protein Kinase C Delta And Jnk Is Required For Interferon-Alpha-Induced Expression Of Ifit4